other material
confidence high
sentiment positive
materiality 0.90
Viking VK2735: 33-week weight loss 22% via weekly dosing; QOW/QM maintenance holds up to 97%/90%
Viking Therapeutics, Inc.
- VK2735 maintenance study (N≈180, BMI≥30): weekly 17.5 mg led to 21.7% mean weight loss from baseline at 33 weeks; placebo gain 0.3%, p<0.0001; no plateau.
- Induction (21 wks weekly): 16-19% weight loss across 15-22.5 mg vs ~0% placebo, p<0.0001; 98% achieved ≥5%, 32% ≥20% loss.
- After transitioning to every-other-week dosing for 12 weeks, maintained up to 97% of Week 21 weight loss vs 61% placebo, p<0.0001.
- Monthly dosing for 12 weeks maintained up to 90% of Week 21 weight loss vs 61% placebo (p=0.0002); separation from placebo by week 4.
- GI AE rates similar to placebo during maintenance; 1% discontinued due to AE in induction; oral maintenance part 2 planned.